Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data
Investigating Chlamydia in US EHR Data
Study Overview
This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting chlamydia-related research to support the chlamydia trachomatis (CT) messenger Ribonucleic acid (mRNA) vaccine program.
There are two primary objectives for this study:
- To determine the validity of ICD, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic codes to identify patients with chlamydial infections using TriNetX EHR data in the US
- To describe screening or diagnostic testing and treatment patterns in patients with chlamydia using TriNetX EHR data in the US
There are also two secondary objectives for this study:
- To explore the feasibility of developing a modified algorithm for identifying patients with chlamydia applicable for Merative MarketScan Commercial Claims and Encounters (CCAE) database based on the findings from the primary objectives
- To compare patient characteristics, use of screening or diagnostic testing, and treatment patterns among patients with chlamydia between TriNetX EHR data and the MarketScan CCAE data in the US
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Chlamydial Infections
-
Age: 14 years - 44 years
-
Gender: All
Inclusion Criteria for Primary Objectives:
- Patients with an ICD-10-CM diagnosis of chlamydia documented in their EHR OR patients with a nucleic acid amplification test (NAAT) result for chlamydia (either positive or negative) during the study period. The index date is the date of the first-recorded diagnosis code, or the date of the first-recorded NAAT result when no diagnosis code for chlamydia exists.
- Patients with at least one visit within 30 days both before and after their index date.
Exclusion Criteria for Primary Objectives:
- Patients with no documented ICD-10-CM diagnosis for chlamydia who possessed unknown laboratory test results for chlamydia during the study period (removed from ICD validation assessment in primary analysis).
- Patients with an ICD-10-CM diagnosis without a corresponding laboratory test (removed from ICD validation assessment in primary analysis).
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
The purpose of this study is to investigate chlamydia. It uses electronic health record (EHR) data from TriNetX, a global health research network, to see if it is a good source for studying chlamydia-related research.
This study evaluates how well certain diagnostic codes identify chlamydia infections and looks at testing and treatment patterns. It also explores if these findings can help develop better ways to identify chlamydia cases in other databases.
- Who can participate: Adults with a documented ICD-10-CM diagnosis of chlamydia or a NAAT result for chlamydia are eligible. Participants need at least one visit within 30 days before and after their index date.
- Study details: Participants will not receive any medication or placebo, as this study uses existing health records to gather information about chlamydia diagnosis and treatment patterns.
Find a study site near you
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Please choose between Voice or SMS based delivery of verification code
or